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Early events driving the initiation and evolution of neoplasms remain poorly defined but involvement of an
instructive or permissive niche has been implicated. In this issue of Cell Stem Cell, Medyouf et al. (2014)
provide insights into the role of the niche in myelodysplastic syndromes, the principle preleukemic disorder
of the hematopoietic system.Myelodysplastic syndrome (MDS) is
considered a clonal disorder of hemato-
poietic cells characterized by bone
marrow failure and predisposition for evo-
lution into acute myeloid leukemia (AML).
The etiology of the disease, including the
cell of origin and the factors driving
leukemic progression, remains poorly un-
derstood. Progress in this area has been
hampered by the inability to faithfully
engraft and propagate human disease in
murine xenograft models, an observation
that has sparked a longstanding debate
about a potential causative or facilitating
role of themicroenvironment in the patho-
genesis of this disease. Medyouf et al., in
a series of challenging experiments, now
implicate mesenchymal cells in disease
initiation and progression, thus creating
a humanized model of MDS (Medyouf
et al., 2014).
In a cohort of genetically heteroge-
neous, lower risk MDS patients, the
authors demonstrate that coinjection
of CD34+ hematopoietic cells, together
with their corresponding in vitro ex-
panded mesenchymal stromal cells
(MCs), into the marrow cavity of
NOD/LtSzscid-IL2rg/ (NSG) mice sig-
nificantly increases reconstitution with
human MDS cells in comparison to trans-
plantationwith CD34+ alone or coinjection
with MCs from age-matched normal bone
marrow.
Repopulating cells were bona fideMDS
cells, as shown by lineage and clonality
tracking, and included a cell type with
long-term repopulation ability. MDS cells
with reconstitution ability (‘‘disease-prop-
agating cells’’) in this experimental
setting were found exclusively within the
CD34+linCD38 subset (albeit tested ina limited number of patients), which,
together with the observation that muta-
tions occur in multiple lineages in MDS
patients, suggests that initiating muta-
tions in this disease occur in primitive
multipotent hematopoietic cells, at least
in a subset of patients.
Transcriptional profiling aimed at inter-
rogating the signaling mechanisms un-
derlying the disease propagating effects
of MCs revealed aberrant gene ex-
pression in MDS-MCs, including gene
sets implicated in intercellular crosstalk,
osteo/adipogenesis, inflammation, and
fibrosis, which are all processes related
to clinico-pathologic characteristics of
subsets of humanMDS. MDS hematopoi-
etic cells were shown to have the capacity
to induce similar transcriptional changes
in MCs in coculture experiments.
Together, the findings make an impor-
tant contribution to the field by establish-
ing a more robust in vivo method to model
human MDS. They further provide exper-
imental support for the view that in MDS,
reciprocal heterotypic signaling between
disease-propagating hematopoietic cells
(and/or their progeny) and mesenchymal
elements within the bone marrow envi-
ronment is required to drive disease
initiation and progression, at least in the
context of the xenograft model. Such
reciprocal signaling may be initiated
through ‘‘reprogramming’’ of mesen-
chymal elements by hematopoietic cells
and subsequently lead to a cascade of
yet-to-be-defined events facilitating dis-
ease progression.
While the findings clearly establish a
functional role for MDS-MCs in the
context of the xenograft model, transla-
tion of this finding to its significance forCell Stem Cehuman disease biology is not entirely
straightforward. First, the cellular, molec-
ular, and functional relationships between
ex vivo expanded MCs and their in situ
niche equivalents remain to be fully
defined. Second, transplanted MCs were
detected only in the injected femur and
disappeared within several weeks, while
long-term engraftment and expansion of
MDS cells was observed in both femurs,
indicating that MCs facilitated initial
homing and engraftment, but were not
required for long-term maintenance of
MDS cells or seeding to the contralateral
femur. While it is tempting to hypothesize
that humanMDS cells, after initial engraft-
ment, may be able to establish their
own self-enforcing murine niche, this
remains to be shown. Future studies,
aimed at elucidating the underlying mo-
lecular mechanisms of MC-facilitated
engraftment of MDS cells, including the
demonstration that this process en-
compasses MC-hematopoietic cell inter-
actions, will shed further light on these
open questions.
Nevertheless, the differential ability of
MDS-MCs (in comparison to normal
MCs) to promote MDS engraftment, and
the heterotypic induction of transcrip-
tional programs in MDS-MCs implicated
in disease biology, strongly argue in favor
of a view in which mesenchymal elements
contribute to disease pathogenesis in
MDS. This notion seems congruent with
emerging experimental insights in support
of a critical role of the mesenchyme in dis-
ease initiation and progression, both in
MDS and other hematopoietic neoplasms
(Walkley et al., 2007, Raaijmakers et al.,
2010, Schepers et al., 2013, Kode et al.,
2014, Scadden, 2012).ll 14, June 5, 2014 ª2014 Elsevier Inc. 695
Figure 1. A Hypothetical Model of Heterotypic Reciprocal Signaling Driving Disease Progression in MDS
Early genetic events in a primitive hematopoietic cell generate ‘‘MDS disease initiating cells’’ that instruct epigenetic reprogramming of mesenchymal (stem) cells.
These reprogrammedmesenchymal cells expand and create amutagenic field ‘‘enabling’’ clonal expansion and genetic evolution of disease-initiating cells at the
cost of normal hematopoiesis.
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the question of how, in principle, reprog-
ramming of mesenchymal cells could
contribute to disease pathogenesis in
MDS within the framework of our current
knowledge of their biology (Morrison and
Scadden, 2014, Frenette et al., 2013)
and the ‘‘enabling’’ processes underlying
neoplastic initiation and progression in
other systems (Hanahan and Weinberg,
2011).
Mesenchymal elements in the bone
marrow constitute a heterogeneous pop-
ulation of functionally distinct cells that
may descend from primitive (stem) cells
in a linear hierarchy. They play critical
roles in the maintenance of tissue compo-
sition and normal HSC and progenitor
subsets (including B cell progenitors)
(HSPCs) and exert immuno-regulatory
functions in adaptive and innate immunity
(i.e. NK, dendritic, and T cells). Hetero-
typic signaling from diseased ‘‘reprog-
rammed’’ mesenchymal (stem) cells may
thus affect other cell types and processes
within the complex cellular circuitry of
the bone marrow, promoting angiogen-
esis, remodeling of the extracellular ma-
trix (fibrosis), and attenuation of normal696 Cell Stem Cell 14, June 5, 2014 ª2014 EHSPC function, facilitation of mutagen-
esis and escape from immunosurveil-
lance for evolving neoplastic clones.
Indeed, these processes reflect clinical
MDS features and gene signatures in
MDS-MCs described by Medyouf et al.,
including upregulation of angiogenic, ma-
trix-modulating and inflammatory path-
ways. This understanding enables a
view in which reciprocal signaling be-
tween mesenchymal cells and other com-
ponents of the niche, perhaps through a
series of (forward-feeding) events, criti-
cally contributes to a permissive or muta-
genic environment, enabling leukemic
evolution of MDS cells, not unlike the
establishment of premetastatic niches in
epithelial tumor biology (Oskarsson
et al., 2014) (Figure 1).
Deciphering the molecular mecha-
nisms driving MC reprogramming and
heterotypic signaling in MDS will provide
key insights to test this hypothetical
view. Of note, the transcriptional profiling
of MDS-MCs conducted by Medyouf
et al. identified molecular commonalities
between patients, despite genetic dis-
ease heterogeneity, which highlight com-
mon triggers that may be amenable tolsevier Inc.therapeutic targeting. Of interest, ‘‘re-
programming’’ may occur through epige-
netic alterations, a view supported by the
observation in this study that a hypoxia
gene signature was maintained under
normoxic culture conditions, but also
supported by longstanding observations
that MDS-MCs display aberrant charac-
teristics after extensive serial passaging
ex vivo. Epigenetic changes could help
explain how alterations in a single mesen-
chymal (stem) cell in early phases of dis-
ease could be transferred into distinct
subtypes of mesenchymal cells upon line-
age progression or to a larger number of
cells through proliferative expansion,
thus creating a ‘‘field’’ of ancillary cells
contributing to malignant progression. It
may also contribute to our understanding
about the therapeutic efficacy of hypome-
thylating therapy, including its potential to
delay leukemic progression.
In conclusion, the study of Medyouf
et al. (2014) marks an important step
toward modeling human MDS. It also
underlines the importance of approaching
preleukemic disorders from a systems
biology point of view, helping us appre-
ciate the intricate circuitry of heterotypic
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Previewscell-cell communication to increase our
fundamental understanding of how pre-
malignant cells utilize the microenviron-
ment to promote their malignant agenda.
These insightswill ultimately result in novel
therapeutic strategies, targeting niche
cells to attenuate leukemic progression.REFERENCES
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The development of curative therapies for genetically complex diseases such as ALS has been delayed by
the lack of relevant disease models. Recent advances using induced-pluripotent-stem-cell-derived moto-
neurons from patients harboring distinct ALS mutations have recapitulated essential disease features and
have identified some common pathways driving disease pathogenesis.Amyotrophic lateral sclerosis (ALS) is a
progressive neurodegenerative disorder
involving the loss of motoneurons in the
spinal cord and motor cortex, leading to
paralysis and premature death. Whereas
most ALS cases are sporadic (sALS),
around 10% are considered familial and
mainly inherited in a dominant manner
(fALS), involving mutations in more than
two dozen genes, including superoxide
dismutase 1 (SOD1), Tar DNA-binding
protein-43 (TDP-43), fused-in-sarcoma
(FUS), and C9orf72. The biology of ALS is
very complex; however, it is known that
thepathology is specific tomotor neurons.
Multiple pathogenic mechanisms have
been proposed to contribute to the selec-
tive motoneuron degeneration, including
alterations in RNA metabolism, mitochon-
drial dysfunction, abnormal protein aggre-
gation, endoplasmic reticulum (ER) stress,excitotoxicity, axonal transport defects,
and gliosis, among other events.
Most cellular and animal models of
ALS involve the expression of supraphy-
siological levels of human transgenes,
mostly involving mutant SOD1 and
TDP-43, which contrasts with the single
allele alteration observed in fALS cases.
Although these ALS models have been
fundamental to investigate disease path-
ogenesis, drugs identified to abrogate
or delay experimental ALS using these
models have failed in clinical trials. These
shortcomings underscore the need for
novel model systems to assess unique
events that may underlie the selective
neuronal vulnerability observed in human
cells. Induced pluripotent stem cells
(iPSCs) generated from ALS patients and
differentiated into motoneurons represent
a promising new tool for studying ALSdisease pathology. Using stem cell ap-
proaches, three recent studies reported
in Cell Stem Cell (Kiskinis et al., 2014;
Chen et al., 2014) and Cell Reports
(Wainger et al., 2014) revealed the occur-
rence of inherited abnormal cellular
phenotypes in ALS patient-derived
motoneurons involving distinct genetic
mutations. Remarkably, common path-
ways of degeneration have emerged
through these studies (Figure 1), opening
the possibility of new and effective drug
screening.
Kiskinis et al. (2014) and Chen et al.
(2014) both established new in vitro
models of ALS by generating iPSC-
derived motoneurons from patients car-
rying SOD1 mutations. Both studies
developed a well-controlled cellular sys-
tem by combining genetic correction of
the SOD1 mutation and whole-genomell 14, June 5, 2014 ª2014 Elsevier Inc. 697
